Human Study Data • PMID 34324435

BPC-157 for Knee Pain:
What the Human Data Shows

📄 3 PubMed citations⚗️ Research chemical

A single intra-articular injection. 11 of 12 patients who received BPC-157 alone reported significant improvement in a retrospective phone survey. Here's what the data shows — and what it doesn't.

🧪 Buy BPC-157 at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items
11/12
Patients reported
significant pain relief
1
Single injection
per patient (study record)
0
Placebo or
control groups

Still logging injections in your Notes app?

A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Common Causes of Knee Pain

Osteoarthritis is the most common cause of knee pain; meniscus tears and ligament tears or sprains are other common causes.

🦴
Osteoarthritis
The most common cause of knee pain, per the knee study (PMID: 34324435). How it progresses and responds to treatment is not covered by the sources cited here.
💥
Meniscus Tears
Another common cause of knee pain, per the knee study (PMID: 34324435). Healing rates are not covered by the sources cited here.
🔗
Ligament Sprains
Ligament tears or sprains are another common cause of knee pain, per the knee study (PMID: 34324435). Recovery outcomes are not covered by the sources cited here.

BPC-157 vs Cortisone Injections

Cortisone is an FDA-approved knee injection. BPC-157 is a very different, far less studied option.

⚠️

Cross-study comparison caveat: BPC-157 and cortisone data come from different studies with different populations and methodologies. Direct comparison should be interpreted cautiously. BPC-157 is not FDA-approved.

Factor Cortisone BPC-157
Pain Relief Duration Not covered by the sources cited here Relief >6 months in only some patients (2025 review); no head-to-head data
Effect on Cartilage Not covered by the sources cited here Not covered by the sources cited here
Repeat Injections Not covered by the sources cited here Single injection in study
Mechanism Suppresses inflammation; evidence not reviewed on this page Preclinical studies suggest angiogenesis & growth-signaling effects (2025 review); not shown in human joints
Adverse Events Not covered by the sources cited here No clinical safety data found (2025 review)
FDA Status FDA-approved, widely available Not FDA-approved, research compound
Evidence Level FDA-approved; evidence not reviewed on this page 1 small retrospective knee survey, no control group; otherwise mostly preclinical

The Knee Pain Study: Data Breakdown

A retrospective chart review at one clinic, with patients followed up by phone. 12 patients with multiple types of knee pain had received a single intra-articular injection of BPC-157 alone. Here's what the survey found.

📋

Study design: Retrospective 1-year chart review with a follow-up phone survey — not a prospective trial. No placebo or control group, no standardized outcome measures, and follow-up time varied (most patients were injected 6 months to 1 year before the survey). The 11 of 12 figure is the BPC-157-only group; a separate small group that received BPC-157 combined with thymosin beta-4 is not included in it. These results need validation in randomized controlled trials.

Patient Response Rates

Significant Pain Relief
BPC-157 alone, patient-reported
11 of 12 (92%)

Common Knee Pain Causes (results not broken down by diagnosis)

OA
Osteoarthritis — the most common cause of knee pain
Meniscus
Meniscus tears — another common cause
Ligament
Ligament tears or sprains — another common cause
📄 Study Citation

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (retrospective study).
PMID: 34324435 • View on PubMed →

Human Safety Data: Very Limited

A very small IV safety pilot (PMID: 40131143) gave BPC-157 at doses up to 20mg IV to healthy adults who had received IV BPC-157 before. No side effects were reported. A pilot this small cannot establish safety: a 2025 systematic review (PMID: 40756949) found no clinical safety data and notes adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.

0
Side effects reported in the small IV pilot (up to 20mg IV)
✓
All biomarkers remained within normal range
Liver Function (AST/ALT)
Remained normal throughout
Normal ✓
Kidney Function (Creatinine)
No renal impact detected
Normal ✓
Cardiac Markers
No measurable effect on tested heart biomarkers (2 people, 3 days)
Normal ✓
Adverse Events Reported
Including mild/transient symptoms
0 events
📄 IV Safety Study

IV BPC-157 safety pilot in a very small group of healthy adults • Up to 20mg dose
PMID: 40131143 • View on PubMed →

📚 2025 Systematic Review

544 articles identified, 36 studies included • Mostly preclinical; no clinical safety data found
PMID: 40756949 • View on PubMed →

How BPC-157 Works in Joints

Preclinical studies link BPC-157 to tissue repair pathways; none of this has been confirmed in human joints or compared with cortisone. Here's what the preclinical research suggests.

🩸
Angiogenesis
Preclinical studies suggest BPC-157 enhances pathways involved in angiogenesis (new blood vessel formation) (2025 review, PMID: 40756949). Whether this improves blood supply or healing in human joints has not been shown.
🧬
Growth Signaling
Preclinical studies link BPC-157 to growth hormone receptor expression and cell-growth signaling pathways involved in tissue repair (2025 review, PMID: 40756949). This has not been confirmed in human joints.

Injection Route Comparison for Joint Issues

The knee study used intra-articular injection — directly into the joint. Here's how three BPC-157 routes compare on the evidence cited here.

🎯
Intra-Articular
Used in the knee study Injected directly into the joint space. Same route as cortisone injections. Requires a medical professional. The only route with human knee data in the sources cited here — one small retrospective survey with no control group.
The route used in the knee study
💉
Subcutaneous
Not studied for knees Injected under the skin. Not the route studied in the knee study, and none of the sources cited here test subcutaneous BPC-157 in humans.
No human evidence for this route in the sources cited here
💊
Oral (Capsule)
Not studied for knees Taken as a capsule. Whether oral BPC-157 has any effect on the knee is not addressed by the sources cited here.
No human evidence for oral dosing in the sources cited here
Vendor

Where to Buy BPC-157

BPC-157 is not FDA-approved and is sold as a research compound. Manufacturing is unregulated, so quality can vary between suppliers.

Browse BPC-157 at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Frequently Asked Questions

In a retrospective chart review of intra-articular injection for multiple types of knee pain (PMID: 34324435), 11 of 12 patients who received BPC-157 alone reported significant improvement in knee pain in a follow-up phone survey. The study abstract does not break results down by diagnosis, and there was no placebo or control group. Larger randomized controlled trials are still needed.

The knee study did not follow every patient for the same length of time: most had their injection 6 months to 1 year before the phone survey. A 2025 systematic review (PMID: 40756949) summarizes the study as reporting relief lasting more than 6 months in only some of the 12 BPC-157-only patients. No study has compared BPC-157 with cortisone head to head, and this data comes from a small retrospective survey.

That has not been tested head to head. A very small IV pilot in healthy adults (PMID: 40131143) reported no side effects at doses up to 20mg, but a 2025 systematic review (PMID: 40756949) found no clinical safety data for BPC-157 and notes adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety. Cortisone injections are FDA-approved; BPC-157 is not FDA-approved.

In the human study, BPC-157 was administered via intra-articular injection — directly into the knee joint space. This is the same route used for cortisone and hyaluronic acid injections. The procedure was performed by a medical professional. Subcutaneous injection was not the route studied, and none of the sources cited here test subcutaneous BPC-157 in humans.

No. BPC-157 is not FDA-approved for any medical condition. It is classified as a research peptide. The human knee data is preliminary: a small retrospective phone survey in which 12 patients received BPC-157 alone, with no placebo control. Always consult a qualified healthcare provider before considering any peptide therapy.

⚕️ Medical Disclaimer

This page is for educational and informational purposes only. It is not medical advice. BPC-157 is not FDA-approved for any medical condition. The studies cited are preliminary — small sample sizes, lack of randomized controlled trials, and limited long-term safety data. Always consult a qualified healthcare professional before making decisions about any peptide, supplement, or treatment protocol. Do not use this information to self-diagnose or self-treat any condition.

Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.